for people ages 18-28 (full criteria)
healthy people welcome
at San Francisco, California
study started
estimated completion
Josh D Woolley, MD/PhD



This study attempts to identify the psychological, behavioral, physiological, and hormonal predictors and mechanisms of an individual's ability to develop cohesion in a group working together as a team; and examine if administration of the prosocial neuropeptide oxytocin enhances the development of team cohesion. Through a deeper understanding of the underlying psychobiological predictors and mechanisms of team cohesion, the prospective identification of individuals whose unique characteristics promote or inhibit the development of group cohesion will become possible.

Official Title

Psychobiological Assessment and Enhancement of Team Cohesion and Psychological Resilience Using a Virtual Team Cohesion Test.


The investigators will study up to one thousand subjects who will be randomized into same-gendered teams of three or volunteer as acquainted groups of three . Teams will be randomized to receive oxytocin or placebo. The investigators will first measure baseline personality traits including prosocial orientation. Cohesion will then be measured using a cooperative, virtual unmanned aerial vehicle (UAV) flying mission. All online behavior will be recorded within the task and all offline, real world, behavior will be video recorded throughout the study by digital cameras for later behavioral coding. To measure biobehavioral synchrony, autonomic physiology will be recorded and saliva samples will be taken throughout behavioral testing.


Unit Cohesion Cohesion Oxytocin Trust Virtual-reality


You can join if…

Open to people ages 18-28

  • Age 18-28
  • Speak English
  • Ability to use a nasal spray

You CAN'T join if...

  • Positive urine pregnancy test
  • History of psychiatric or neurologic disorder
  • Use of illicit drugs in the past month
  • History of moderate-severe alcohol use disorder as defined by DSM-V criteria
  • Sensitivity to preservatives (in particular E 216, E 218 and chlorobutanol hemihydrate)
  • Nasal obstruction, discharge, or bleeding
  • Habitually drinks large volumes of water
  • Taking testosterone, estrogen/progesterone supplement, or serotonin-1a receptor agonists/antagonists
  • Currently meets Diagnostic and Statistical Manual-5 (DSM-V) criteria for severe major depressive disorder with suicidal thoughts or actions


  • San Francisco VA Medical Center
    San Francisco California 94121 United States

Lead Scientist

  • Josh D Woolley, MD/PhD
    Dr. Woolley has been studying the underpinnings of social deficits in schizophrenia and has examined how oxytocin might be a useful treatment for these social deficits. People with schizophrenia often have functionally significant social cognitive deficits, and there are currently no available pharmacological treatments that target these deficits.


in progress, not accepting new patients
Start Date
Completion Date
University of California, San Francisco
Phase 1
Study Type
Last Updated